Results 61 to 70 of about 33,467 (159)

Therapy With Doxycycline and Hydroxychloroquine Enables Surgical Excision of Ulcerated Cutaneous Granulomas in a Patient With Ataxia Telangiectasia

open access: yesPediatric Dermatology, Volume 43, Issue 4, Page 929-932, July/August 2026.
ABSTRACT The rubella virus vaccine strain can cause granulomas in patients with inborn errors of immunity that may evolve into chronic, recalcitrant ulcers. This report details treatment of ulcerated rubella granulomas in a patient with ataxia telangiectasia with doxycycline and hydroxychloroquine resulting in partial ulcer healing within 4 weeks ...
Luis Murguía‐Favela   +6 more
wiley   +1 more source

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin

open access: yesViruses, 2012
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C.
Osamu Yokosuka   +8 more
doaj   +1 more source

Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis

open access: yesInternational Journal of Infectious Diseases, 2019
Objectives: Lassa fever (LF) causes annual outbreaks in endemic regions with high mortality of symptomatic patients. Ribavirin is recommended as standard treatment for LF in national and international guidelines but the evidence base for this ...
Kirsten Alexandra Eberhardt   +5 more
doaj   +1 more source

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2016
Ribavirin remains an important component of hepatitis C treatment in certain clinical scenarios, but it causes hemolytic anemia. A quantitative understanding of the ribavirin exposure‐anemia relationship is important in dose individualization ...
LS Wu   +4 more
doaj   +1 more source

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

open access: yesBMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed   +6 more
doaj   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

open access: yesDiseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran   +10 more
doaj   +1 more source

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

open access: yesClinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C   +4 more
doaj  

Ribavirin

open access: yesInfectious Diseases Newsletter, 1985
openaire   +2 more sources

Compression of Ribavirin to 35 GPa. [PDF]

open access: yesCryst Growth Des
Tiwari B, Parsons S, Giordano N.
europepmc   +1 more source

Home - About - Disclaimer - Privacy